Compare · BLI vs MNMD
BLI vs MNMD
Side-by-side comparison of Berkeley Lights Inc. (BLI) and Mind Medicine (MindMed) Inc. (MNMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLI and MNMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MNMD has more recent analyst coverage (16 ratings vs 13 for BLI).
- Company
- Berkeley Lights Inc.
- Mind Medicine (MindMed) Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- +19.56%
- 1Y return
- -
- +28.80%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 13
- 16
Berkeley Lights Inc.
Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. The company was incorporated in 2011 and is headquartered in Emeryville, California.
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Latest BLI
- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
- SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)
- SEC Form 15-12G filed by Berkeley Lights Inc.
- Kadia Siddhartha returned 1,240,689 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chiminski John R returned 112,465 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Silvester Peter returned 64,596 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Hopfield Jessica returned 105,207 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Joshi Mehul returned 65,013 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Hobbs Eric returned 244,816 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Moritz Michael J returned 1,451,925 shares to the company (SEC Form 4)
Latest MNMD
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)
- Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel sold $73,623 worth of shares (5,600 units at $13.15), decreasing direct ownership by 1% to 425,025 units (SEC Form 4)
- SEC Form 144 filed by Mind Medicine (MindMed) Inc.
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
- MindMed Announces New Employee Inducement Grant
- MindMed Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits